Vera Therapeutics (VERA) Stock Price, News & Analysis

Company Overview

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates.

The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.

Key Stats

• Today's Range: $31.31 to $32.35
• 50-Day Range: $28.89 to $43.15
• 52-Week Range: $21.15 to $56.05
• Volume: 1.03 million shs
• Average Volume: 2.09 million shs
• Market Capitalization: $2.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $81.15
• Consensus Rating: Moderate Buy

Vera Therapeutics Stock Analysis - MarketRank™

Vera Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 364th out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vera Therapeutics has a consensus price target of $81.15, representing about 151.4% upside from its current price of $32.28.

Amount of Analyst Coverage

Vera Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vera Therapeutics are expected to grow in the coming year, from ($6.46) to ($4.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vera Therapeutics is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vera Therapeutics is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vera Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.31% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 9.42.

Change versus previous month

Short interest in Vera Therapeutics has recently increased by 1.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vera Therapeutics does not currently pay a dividend.

Dividend Growth

Vera Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

Vera Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 31 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,658,080.00 in company stock.

Percentage Held by Insiders

15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 8/18/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VERA
• CIK: 1831828
• Web: veratx.com
• Phone: 650-770-0077
• Fax: N/A
• Employees: 40
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vera Therapeutics: $81.15
• High Price Target: $125.00
• Low Price Target: $34.00
• Potential Upside/Downside: +151.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$299.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.13%
• Return on Assets: -66.79%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 10.92
• Quick Ratio: 10.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.48 per share
• Price / Book: 3.81

Miscellaneous

• Outstanding Shares: 72,060,000
• Free Float: 60,605,000
• Market Cap: $2.33 billion
• Optionable: Optionable
• Beta: 0.92